"Lansoprazole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Descriptor ID |
D064747
|
| MeSH Number(s) |
D02.886.640.074.249 D03.383.725.024.249 D03.633.100.103.034.249
|
| Concept/Terms |
Lansoprazole- Lansoprazole
- Lansoprazol
- 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
- Lansoprazoles
|
Below are MeSH descriptors whose meaning is more general than "Lansoprazole".
Below are MeSH descriptors whose meaning is more specific than "Lansoprazole".
This graph shows the total number of publications written about "Lansoprazole" by people in this website by year, and whether "Lansoprazole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 3 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 3 | 3 |
| 2015 | 3 | 0 | 3 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lansoprazole" by people in Profiles.
-
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019 10; 19(10):1109-1120.
-
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015 Nov; 64(11):1715-20.
-
Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. Ann Am Thorac Soc. 2015 Jun; 12(6):878-85.
-
Proton pump inhibitors and vascular function: A prospective cross-over pilot study. Vasc Med. 2015 Aug; 20(4):309-16.
-
Obesity in children with poorly controlled asthma: Sex differences. Pediatr Pulmonol. 2013 Sep; 48(9):847-56.
-
In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine. Digestion. 2012; 86(2):171-7.
-
Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA. 2012 Jan 25; 307(4):373-81.
-
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011 Oct; 141(4):1314-22, 1322.e1-5.
-
Failures in a proton pump inhibitor therapeutic substitution program: lessons learned. Dig Dis Sci. 2007 Oct; 52(10):2813-20.
-
Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr. 2007 Mar; 150(3):262-7, 267.e1.